Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia
AssigneeImmunoGen, Inc.
InventorPatrick Zweidler-McKay
Life of this patent
Estimating the term…
Abstract
Methods and uses of immunoconjugates that bind to CD123 (e.g., pivekimab sunirine) in patients with acute myeloid leukemia (AML) are provided. Such immunoconjugates can be used as monotherapies or can be used in combination with BCL-2 inhibitors (e.g., venetoclax), and/or hypomethylating agents (e.g., azacitidine or decitabine) to prepare patients with AML for hematopoietic stem cell transplant and/or to achieve complete remissions in patients with AML, including those with poor prognostic markers.
Claims115
A method of treating an unfit newly diagnosed acute myeloid leukemia (ND AML) in a subject comprising administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent.
A method for treating an acute myeloid leukemia (AML) in a subject comprising administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent, wherein the administration achieves a complete response (CR), CR (clinical) with partial hematological recovery (CRh), CR with incomplete platelet recovery (CRp), or CR (clinical) with incomplete recovery (CRi) with a duration of at least 3 months.
A method for treating a FLT3 TKD, IDH1mut, NMP1mut, and/or K/NASmut acute myeloid leukemia (AML) in a subject with comprising administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent.
A method of clearing minimal residual disease (MRD) in a human subject with acute myeloid leukemia (AML) comprising administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent, wherein the MRD is cleared in 2 months or less.
A method of preparing a subject with acute myeloid leukemia (AML) for a hematopoietic stem cell transplant (HSCT), the method comprising administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent.
A method for treating an acute myeloid leukemia (AML) in a subject comprising (i) administering to the subject a combination therapy comprising (i) pivekimab sunirine, (ii) a BCL-2 inhibitor, and (iii) a hypomethylating agent and (ii) subsequently administering a hematopoietic stem cell transplant (HSCT) to the subject.
A method for treating an acute myeloid leukemia (AML) in a subject comprising administering a hematopoietic stem cell transplant (HSCT) to the subject, wherein the subject has previously been treated with pivekimab sunirine.
A method of treating an unfit newly diagnosed acute myeloid leukemia (ND AML) in a subject comprising administering to the subject (i) 0.045 mg/kg pivekimab sunirine, (ii) venetoclax, and (iii) azacitidine, wherein the administration achieves a complete response (CR), CR (clinical) with partial hematological recovery (CRh), CR with incomplete platelet recovery (CRp), or CR (clinical) with incomplete recovery (CRi) with a duration of at least 3 months.
A method of treating relapsed and/or refractory AML in a subject comprising administering to the subject (i) 0.045 mg/kg pivekimab sunirine, (ii) venetoclax, and (iii) azacitidine, wherein the administration achieves a complete response (CR), CR (clinical) with partial hematological recovery (CRh) or CR (clinical) with incomplete recovery (CRi) complete response with a duration of at least 2 months.
Dependencies are inferred from the claim text.